Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient demographics at baseline

From: Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

  All patients, N = 61 Patients with paired tumor samples, N = 54
Mean age (range) 67 [53–86] 67 [53–86]
Tumor size (mean, range) 1.7 [0.8–3.5] 1.7 [0.8–3]
Clinical tumor stage
 T1 34 (55.7%) 30 (55.6%)
 T2 27 (44.3%) 24 (44.4%)
Clinical lymph nodal status
 N0 58 (95.1%) 53 (98.1%)
 N1 3 (4.9%) 1 (1.9%)
Histological grade
 G1 23 (37.7%) 21 (38.9%)
 G2 32 (52.4%) 29 (53.7%)
 G3 2 (3.3%) 2 (3.7%)
 NA 4 (6.6%) 2 (3.7%)
ECOG
 0 54 (88.5%) 47 (87.0%)
 1 7 (11.5%) 7 (13.0%)
Arms
 Letrozole 21 (34.4%) 20 (37.0%)
 mVNB 20 (32.8%) 15 (27.8%)
 Letrozole+mVNB 20 (32.8%) 19 (35.2%)
  1. NA not available; mVNB metronomic vinorelbine